Thiopurine metabolite testing in inflammatory bowel disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 3, 2016, Pages 553-560

  Goldberg, Rimma ^a,b   Moore, Gregory ^a,c   Cunningham, Georgina ^b   Schulberg, Julien ^b   Marsh, Philip ^a   Brown, Steven ^b   Connell, William ^b   Lust, Mark ^b   Kamm, Michael A ^b,d,e   Bell, Sally ^b  

^a SOUTHERN HEALTH   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

IBD; Metabolite testing; Thiopurines

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; DRUG METABOLITE; MERCAPTOPURINE; TIOGUANINE;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; ASSAY; CROHN DISEASE; CYTOPENIA; DRUG BLOOD LEVEL; DRUG TRANSFORMATION; HUMAN; INFLAMMATORY BOWEL DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; THIOPURINE METABOLITE TESTING; TREATMENT RESPONSE; ULCERATIVE COLITIS; COHORT ANALYSIS; DRUG MONITORING; INFLAMMATORY BOWEL DISEASES; METABOLISM; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

6-MERCAPTOPURINE; AZATHIOPRINE; COHORT STUDIES; DRUG MONITORING; HUMANS; INFLAMMATORY BOWEL DISEASES; RETROSPECTIVE STUDIES; THIOGUANINE; TREATMENT OUTCOME;

EID: 84959162446     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13210     Document Type: Article

References (32)

1. Gearry R, Barclay M, Burt M, Collett J, Chapman B. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol. Drug Saf. 2004; 13: 563-7.
2. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England J. Med. 2010; 362: 1383-95.
3. Willoughby JMT, Kumar PJ, Beckett J, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 731: 944-7.
4. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in the management of Crohn's disease. Dig. Dis. 1975; 20: 721-6.
5. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of ulcerative colitis. Gastroenterology 1975; 69: 96-9.
6. Sparrow M. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 2007; 5: 209-14.
7. Dassopoulos T, Dubinsky MC. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment. Pharmacol. Ther. 2013 Nov; 17: 163-75.
8. Cosnes J, Bourrier A, Laharie D et al. Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial. Gastroenterology 2013 Oct; 145: 758-65.
9. Dubinsky MC, Lamothe S, Yang YH et al. Pharmacogenomics and metabolite measurement of 6-Mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000 Apr, 118: 705-13.
10. Moreu AC. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflamm. Bowel Dis. 2014 Mar; 20: 464-71.
11. Khan KJ. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 2011; 106: 630-42.
12. Timmer A. Azathioprine and 6- mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2012; 9: Cd000478.
13. Elion GB. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann. NY Acad. Sci. 1993; 685: 400-7.
14. Aarbakke J. Thiopurine biology and pharmacology. Trends Pharmacol. Sci. 1997 Jan; 18: 3-7.
15. Krynetski EY. Pharmacogenetics of cancer therapy: getting personal. Am. J. Hum. Genet. 1998 Jul; 63: 11-6.
16. Dubinsky M, Vasiliauskas EDD, Singh HDD et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125: 298-303.
17. Barrett G. Initiating azathioprine for Crohn's disease. Clin. Gastroenterol. Hepatol. 2012; 10: 460-5.
18. Blaker PA. Mechanism of allopurinol induced TPMT inhibition. Biochem. Pharmacol. 2013 Aug 15; 86: 539-47.
19. Sparrow M, Sparrow MP, Hande SA, Friedman S et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment. Pharmacol. Ther. 2007; 22: 441-6.
20. Dubinsky MC. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 2005; 100: 2239-47.
21. Roblin X. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm. Bowel Dis. 2011; 17: 12.
22. Clin. Chem. 1998; 44: 551.
23. Dubinsky M. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin. Gastroenterol. Hepatol. 2004; 2: 731-43.
24. Chouchana L, Narjoz C, Beaune P, Loriot MA. Roblin X Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2012 Jan; 35: 15-36.
25. de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Review Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 2007 Dec; 4: 686-94.
26. Haines ML, Ajlouni Y, Irving PM et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm. Bowel Dis. 2011 Jun; 17: 1301-7.
27. Moreau AC, Laporte S, Del Tedesco E et al. Association between thiopurines metabolites levels and clinical remission in IBD patients: an updated meta-analysis. Gastroenterology 2013; 144: S-92.
28. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006 Apr, 130: 1047-53.
29. Kennedy NA, Asser TL, Mountifield RE, Doogue MP, Andrews JM, Bampton PA. Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. Intern. Med. J. 2013; 43: 278-86.
30. Hindorf U, Lindqvist M, Peterson C et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006; 55: 1423-31.
31. Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J. Crohns Colitis 2012 Oct; 6: 905-12.
32. de Graaf P1, de Boer NK, Wong DR et al. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy. Br. J. Pharmacol. 2010 Jul; 160: 1083-91.